Alliance Between Pharma and Nonprofits to Speed Development of Tuberculosis Therapies
AstraZeneca, Bayer, Sanofi, Tibotec, TB Alliance, and the World Health Organization agreed to share information on tuberculosis (TB) compounds within their respective drug pipelines, according to the Critical Path to TB Drug Regimens (CPTR). The purpose of the agreement is to promote information sharing around scientific and clinical studies so that partners can identify opportunities to test compounds in combination. Under the agreement, if two or more organizations choose to work together to further develop a regimen, they will enter into a separate arrangement that defines the rights and responsibilities of each party
AstraZeneca, Bayer, Sanofi, Tibotec, TB Alliance, and the World Health Organization agreed to share information on tuberculosis (TB) compounds within their respective drug pipelines, according to the Critical Path to TB Drug Regimens (CPTR). The purpose of the agreement is to promote information sharing around scientific and clinical studies so that partners can identify opportunities to test compounds in combination. Under the agreement, if two or more organizations choose to work together to further develop a regimen, they will enter into a separate arrangement that defines the rights and responsibilities of each party.
“Today’s announcement will accelerate efforts to simplify and improve TB drug regimens,” said Mel Spingleman, president and CEO of TB Alliance, in a press release. “It is critical that we decrease the complexity and duration of treatment, make the treatment of multidrug-resistant TB significantly easier and more tolerable, and make new regimens available to all those who need them as quickly as possible.”
CPTR is working closely with regulatory scientists at FDA, EMA, and other regulatory bodies in China, India, and African countries to develop the tools that will allow testing of new TB drugs in combination. The group’s goal is to shorten the development timeline. Under the leadership of the Critical Path Institute, CPTR’s Regulatory Science Consortium focuses on establishing consensus about preferred standards, methods, and tools for developing new TB drug regimens, and on obtaining official acceptance from international regulatory authorities. CPTR was cofounded by the Bill & Melinda Gates Foundation, the Critical Path Institute, and the TB Alliance with the purpose of fostering collaboration to reduce the time it takes to develop novel TB drug regimens, regardless of sponsor.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
